Dr. Hamlin on Study of Cerdulatinib in Non-Hodgkin Lymphoma

Paul A. Hamlin, MD
Published: Friday, Jun 23, 2017



Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

Cerdulatinib is an oral dual Syk/JAK inhibitor that is currently being evaluated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent lymphomas such as follicular lymphoma and peripheral T-cell lymphoma.

This is an open-label, phase II cohort-driven expansion study, preliminary results of which are being presented at the 2017 European Hematology Association Congress.
 


Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

Cerdulatinib is an oral dual Syk/JAK inhibitor that is currently being evaluated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent lymphomas such as follicular lymphoma and peripheral T-cell lymphoma.

This is an open-label, phase II cohort-driven expansion study, preliminary results of which are being presented at the 2017 European Hematology Association Congress.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x